The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with multi parametric MRI (mpMRI) compared to diagnostic transurethral resection of bladder tumor (TURBT) in patients (pts) with suspected muscle-invasive bladder cancer (MIBC): A pilot study.
 
Nataliya Mar
Speakers' Bureau - Aveo; Eisai; Merck; Seagen; Tempus
Research Funding - Gilead Sciences
 
Amanda Macaraeg
No Relationships to Disclose
 
Ali Raad
No Relationships to Disclose
 
Dalia Kaakour
No Relationships to Disclose
 
Arash Rezazadeh
Stock and Other Ownership Interests - ECOM Medical
Consulting or Advisory Role - AimedBio; AstraZeneca; aveo; Bayer; Bicycle Therapeutics; Eisai; Exelixis; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Amgen; AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Gilead Sciences; Janssen; Myovant Sciences; Pfizer; Sanofi
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eikon Therapeutics; Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); navir (Inst); Novartis (Inst); POINT Biopharma (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bayer; Eisai; Exelixis; Janssen
 
Michael Daneshvar
Consulting or Advisory Role - CG Oncology; ImmunityBio